10x Genomics, Inc.(TXG)Company Profile & Business
NASDAQ

Company Profile

Business overview, scale, and footprint

Company Name10x Genomics, Inc.
Ticker SymbolTXG
ExchangeNMS
SectorHealthcare
IndustryMedical Devices
Employees1,178
CEODr. Serge Saxonov Ph.D.
Founded2012
HeadquartersPleasanton, CA, United States
CountryUnited States
Next Earnings DateNov 5, 2026

Business Overview

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides.

In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns.

The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions.

The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Insider Transactions

Open-market activity and option exercises

Insider Activity Summary

Insider trading activity for 10x Genomics, Inc. (TXG) between Nov 14, 2024 and Sep 22, 2026 consists of 103 total transactions. Among these, company executives and board members conducted 67 buys (totaling 1,764,861 shares) and 36 sells (totaling 303,201 shares). This activity resulted in a net change of 1,461,660 shares, reflecting net buying interest with an estimated net acquisitions value of $293.70M.

103 insider transactions found. Showing 10 of 103 transactions.

Show:entries
Insider NameRelation to CompanyShares ChangedPriceTransaction Date
SULIMAN SHEHNAAZDirector-292$78.20Sep 22, 2026
SULIMAN SHEHNAAZDirector-614$79.51Sep 22, 2026
SULIMAN SHEHNAAZDirector-1,325$80.82Sep 22, 2026
SULIMAN SHEHNAAZDirector-2,270$81.67Sep 22, 2026
SULIMAN SHEHNAAZDirector-1,222$82.28Sep 22, 2026
Saxonov SergeChief Executive Officer-1,000$78.23Sep 22, 2026
Saxonov SergeChief Executive Officer-2,000$79.62Sep 22, 2026
Saxonov SergeChief Executive Officer-9,300$80.90Sep 22, 2026
Saxonov SergeChief Executive Officer-9,900$81.83Sep 22, 2026
Saxonov SergeChief Executive Officer-2,800$82.36Sep 22, 2026
Page 1 of 11 (103 total transactions)